UroAlert - GU Oncology Weekly

December 03, 2025

Videos

Peer-to-Peer Clinical Conversations

24-Month Follow-Up Data from Phase 3 BOND-003 Cohort C Trial - Mark Tyson

Mark Tyson

Zachary Klaassen speaks with Mark Tyson about 24-month follow-up data from BOND-003 Cohort C evaluating cretostimogene grenadenorepvec in BCG-unresponsive CIS patients.

LUNAR Trial: Neoadjuvant Lutetium-PSMA Plus SBRT Evaluated in Oligometastatic Prostate Cancer - Amar Kishan & Jeremie Calais

Amar Kishan

Zachary Klaassen speaks with Amar Kishan and Jeremie Calais about the LUNAR trial.

Beyond the Abstracts

Inflammatory Bowel Disease vs. Adverse In-Hospital Outcomes after Radical Prostatectomy - Beyond the Abstract

Clinical, Pathologic, and Genetic Correlates of Nuclear Grade in von Hippel-Lindau-associated Renal Cell Carcinoma - Beyond the Abstract

Conference Coverage

SUO 2025: Comparison of Prostate-specific Antigen Response Among Patients with Metastatic Castration-sensitive Prostate Cancer Treated with Apalutamide or Abiraterone Acetate – A Real-world Study

SUO 2025: Trials in Progress - CORE-008 Cohort B: Evaluating Intravesical Cretostimogene Grenadenorepvec in Patients with High Risk, BCG-Exposed NMIBC

SUO 2025: Durable 24 Month Outcomes from BOND-003 Cohort C: Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with CIS

SUO 2025: Healthcare Resource Utilization and Medical Costs in Patients with Metastatic Castration Sensitive Prostate Cancer Initiating Apalutamide or Darolutamide in the United States

SUO 2025: Five-Year Follow-up Results from the Phase 3 KEYNOTE-564 Study of Adjuvant Pembrolizumab for the Treatment of Clear Cell Renal Cell Carcinoma

Physician-Scientist Review Articles

A Clinical Trial of Adjuvant Nivolumab Following Chemoradiation in Localized Muscle-Invasive Urothelial Cancer - Expert Commentary

Performance Large Language Models in Guiding Bladder Cancer Management - Expert Commentary

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Combining molecular patterns and clinical data for better immune checkpoint inhibitor prediction in metastatic urothelial carcinoma.

Incidental Bladder Lesions on Prostate Multiparametric MRI: Prevalence and Factors Associated with Bladder Carcinoma.

Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases.

Bladder EpiCheck triggered Photodynamic Diagnosis biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy.

Assessing risk stratification in Bacillus Calmette-Guérin-treated high-grade Ta nonmuscle-invasive bladder cancer patients.

Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients.

Therapeutic Intensification Based on Immune Checkpoint Inhibitors in Non-Muscle Invasive Bladder Cancer: State of the Art and Future Perspectives.

Trends in Treatment Patterns and Outcomes Among Patients Diagnosed With Nonmuscle-Invasive Bladder Cancer in the United States.

JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.

Urinary extracellular vesicles for high-precision bladder cancer subtyping and prognosis.

Penile & Urethral Cancers

The Value of FDG PET/CT in Penile Cancer: An Update.

Penile Cancer Treatments and Their Psychiatric Sequelae: A National Analysis.

Histology-Specific Survival in Penile Squamous Cell Carcinoma: A SEER-Based Study Highlighting Human Papillomavirus Status and Prognostic Subtypes.

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines.

A call for raising public awareness and improving outcomes of penile cancer.

Renal Cancer

Deciphering genetic susceptibility to clear cell renal cell carcinoma.

Any Role of FDG PET in Renal Cancer?

Clinical and Pathological Features Associated with Chromophobe Renal Cell Carcinoma Recurrence: Analysis from a Nationwide Cohort.

Targeting of HIF2-driven cachexia in kidney cancer.

Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group.

Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group.

Stereotactic body radiotherapy for renal tumors: a prospective phase 2 clinical trial.

Predictors of Survival and Recurrence After Partial or Radical Nephrectomy in Women with Localized Renal Cell Carcinoma: A Multicenter Analysis.

Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study.

Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.

Prostate Cancer

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer.

Co-PSMA Trial Achieves Primary Endpoint

Androgen receptor splice variant expression and prostate cancer recurrence after salvage therapy.

Predictors of long-term disease-free survival with stereotactic body radiotherapy for metachronous oligometastatic prostate cancer.

Validation of Artificial Intelligence-enhanced Stimulated Raman Histopathology for Intraoperative Margin Assessment During Robot-assisted Radical Prostatectomy: Preliminary Results from the ROBOSPEC Study.

Yttrium-90 Radioembolization for Androgen-Independent Prostate Cancer Metastasis to the Liver.

Comparison of same-day discharge robotic-assisted radical prostatectomy in an ambulatory surgery center versus hospital setting.

A Computational Pathology Model to Predict Docetaxel Benefit in Localized High-Risk and Metastatic Prostate Cancer.

Automated imaging as an adjunct to serum and clinical biomarkers: a new validated prediction tool for metastatic castration-resistant prostate cancer.

Radical Prostatectomy Combined with Prostate Specific Membrane Antigen-radioguided Lymph Node Dissection is Associated with Longer Treatment-free Survival for Patients with Primary Lymph Node-positive Prostate Cancer.

Real-World Medical Device Reports of SpaceOAR Hydrogel Spacer: Analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) Database.

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.

Extending Current Guideline-recommended Prostate-specific Antigen Density Thresholds for Improving Benefit/Harm Balance in Risk-based Magnetic Resonance Imaging-directed Prostate Cancer Diagnosis, from the Community-based Multicentre MR-PROPER Study.

Rapid Eradication of Extensive Spinal Metastases in a Prostate-Cancer Patient Taking Androgen-deprivation Therapy, Chemotherapy, and Oral Recombinant Methioninase on a Low-Methionine Diet.

Comprehensive Outcome Analysis of Single-Port Robot-Assisted Radical Prostatectomy.

External beam radiotherapy for prostatic cancers: 2025 update.

Micro-ultrasound for prostate cancer.

Preventative cancer screening among African and Afro-Caribbean immigrants.

Primary Staging of Intermediate- and High-Risk Prostate Cancer Using [18F]PSMA-1007 PET/CT and [18F]NaF PET/CT: A Head-to-Head Comparison of Diagnostic Accuracy, Staging, and Patient Management.

Radiation Reprograms Fibroblasts to Drive Prostate Cancer Therapy Resistance.

Prognostic significance of magnetic resonance imaging-detected extraprostatic extension in localized prostate cancer.

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer.

Rethinking Gleason pattern quantification in predicting metastasis: results of 20 years of follow-up in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

PuraBond® in Robot-Assisted Radical Prostatectomy (RARP): Exploring a Novel Haemostatic Strategy Using Self-Assembling Peptides.

NUAK2 is a therapeutically tractable regulator of RNA splicing and tumor progression in neuroendocrine prostate cancer.

Gleason Score 3 + 4 (Grade Group 2) Prostate Cancer on Biopsy and Postoperative Pathological Upgrading: A Systematic Review and Meta-Analysis.

[18F]Flotufolastat PET/MRI in Patients with Suspected Prostate Cancer: Correlation with Histopathologic Biopsy Results.

Validation and context-dependent effects of a prostate cancer polygenic risk score in the All of Us Research Program.

EZH2 crosstalk with RNA methylation promotes prostate cancer progression through modulation of m6A autoregulation pathway.

Single-Arm Investigator-Initiated Clinical Trial to Improve Germline Testing in At-Risk Patients With Prostate Cancer (IMPRINT).

The Legacy of Chattel-Slavery and Its Association with Prostate Cancer Incidences in the Southeastern US.

USP21/YBX1/HIF1-α promotes the progression of prostate cancer.

Upper Tract Tumors

Exploratory analysis of the molecular and genomic landscape of upper tract urothelial carcinoma using long-read sequencing.

Testicular Cancer

Immune cell profiling of peripheral blood in long-term testicular germ cell tumor survivors.

Late relapse of testicular germ cell tumor: An individual patient data meta-analysis of disease characteristics, treatments, and oncological outcomes.

Spatial patterns of testicular cancer diagnosis in Australia, 2010-2019.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC